This website uses cookies

Full Text

See more details

X (2)

Mendeley (7)

1

CITATION

1 Total citation

0 Recent citations

0.16 Field Citation Ratio

0.05 Relative Citation Ratio

publications

1

supporting

0

mentioning

0

contrasting

0

Smart Citations

1

0

0

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• Moorthi, R.N., Moe, S.M., Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int. 84 (2014), 886–894.
• Delanaye, P., Warling, X., Moonen, M., Smelten, N., Jouret, F., Krzesinski, J.M., Maillard, N., Pottel, H., Cavalier, E., Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients. Sci. Rep. 7 (2017), 3–10.
• Robling, A.G., Niziolek, P.J., Baldridge, L.A., Condon, K.W., Allen, M.R., Alam, I., Mantila, S.M., Gluhak-Heinrich, J., Bellido, T.M., Harris, S.E., Turner, C.H., Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 283 (2008), 5866–5875.
• Cejka, D., Herberth, J., Branscum, A.J., Fardo, D.W., Monier-Faugere, M.C., Diarra, D., Haas, M., Malluche, H.H., Sclerostin and dickkopf-1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 6 (2011), 877–882.
• Behets, G.J., Viaene, L., Meijers, B., Blocki, F., Brandenburg, V.M., Verhulst, A., D'Haese, P.C., Evenepoel, P., Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS One 12 (2017), 1–12.
• Delanaye, P., Paquot, F., Bouquegneau, A., Blocki, F., Krzesinski, J.-M., Evenepoel, P., Pottel, H., Cavalier, E., Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol. Dial. Transplant., 2017, 1–7.
• Delanaye, P., Krzesinski, J.M., Warling, X., Moonen, M., Smelten, N., Médart, L., Bruyère, O., Reginster, J.Y., Pottel, H., Cavalier, E., Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron. - Clin. Pract. 128 (2014), 127–134.
• Cejka, D., Parada-Rodriguez, D., Pichler, S., Marculescu, R., Kramer, I., Kneissel, M., Groos, T., Reisinger, A., Pahr, D., Monier-Faugere, M.C., Haas, M., Malluche, H.H., Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. Kidney 90 (2016), 828–834.
• Qureshi, A.R., Olauson, H., Witasp, A., Haarhaus, M., Brandenburg, V., Wernerson, A., Lindholm, B., Söderberg, M., Wennberg, L., Nordfors, L., Ripsweden, J., Barany, P., Stenvinkel, P., Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 88 (2015), 1356–1364.
• Malluche, H.H., Davenport, D.L., Canto, T., Monier-Faugere, M.C., Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin. J. Am. Soc. Nephrol. 9 (2014), 1254–1262.